[
  {
    "id": "1cc83f27a9327250",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-14T17:07:51.917Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:07:51.918Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "671b5be6d8315723",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PACLITAXEL may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PACLITAXEL may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-14T17:07:51.921Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:07:51.921Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "2b7661089300fe4b",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CISPLATIN may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CISPLATIN may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-14T17:07:51.922Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:07:51.922Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "1c970c838006b96e",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DOXORUBICIN HYDROCHLORIDE may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRCA1, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DOXORUBICIN HYDROCHLORIDE may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-14T17:07:51.923Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:07:51.923Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "826d6b895cc51faf",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TALAZOPARIB may be repurposed to treat breast cancer",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8973333333333333,
      "mechanism": "Targets BRCA1, EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TALAZOPARIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-14T17:07:51.924Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:07:51.924Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "78956a4df5f0936d",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-14T17:09:56.392Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:09:56.392Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "6529dc724f0fc887",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PACLITAXEL may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PACLITAXEL may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-14T17:09:56.394Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:09:56.394Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "07a892b2ac9ea4f7",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CISPLATIN may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CISPLATIN may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-14T17:09:56.395Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:09:56.395Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "0d819b5b19beccc9",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DOXORUBICIN HYDROCHLORIDE may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRCA1, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DOXORUBICIN HYDROCHLORIDE may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-14T17:09:56.397Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:09:56.397Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "d9e12fe4a558567c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TALAZOPARIB may be repurposed to treat breast cancer",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8973333333333333,
      "mechanism": "Targets BRCA1, EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TALAZOPARIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-14T17:09:56.398Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:09:56.398Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "e0559e8e2b8525d7",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-14T17:14:32.111Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:14:32.111Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "40f70a7eaa32484c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PACLITAXEL may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PACLITAXEL may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-14T17:14:32.113Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:14:32.113Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "4f7c259d92419cac",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CISPLATIN may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CISPLATIN may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-14T17:14:32.114Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:14:32.114Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "884a1552fc5e4ad1",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DOXORUBICIN HYDROCHLORIDE may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRCA1, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DOXORUBICIN HYDROCHLORIDE may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-14T17:14:32.116Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:14:32.116Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "1082b04dad17b905",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TALAZOPARIB may be repurposed to treat breast cancer",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8973333333333333,
      "mechanism": "Targets BRCA1, EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TALAZOPARIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-14T17:14:32.117Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:14:32.117Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "c575cb7478b83cef",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-14T17:19:16.048Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:19:16.048Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "fbd329136978d6c1",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "totalScore": 0.839,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-14T17:19:16.052Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:19:16.052Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "26ef8d8667066d12",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "totalScore": 0.839,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-14T17:19:16.054Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:19:16.054Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "6c7dbfc27710818e",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "totalScore": 0.839,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-14T17:19:16.057Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:19:16.057Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "dc65a5155e5f5a44",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "totalScore": 0.839,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-14T17:19:16.059Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:19:16.059Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "69f3d322bce47b57",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "SORAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "SORAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-14T17:27:00.571Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:27:00.571Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "0aeec506966dca9f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "BINIMETINIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "BINIMETINIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-14T17:27:00.573Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:27:00.573Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "fd0e6ca0f74132c7",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DABRAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DABRAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-14T17:27:00.575Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:27:00.575Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "8cd08cbe41923430",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VEMURAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VEMURAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-14T17:27:00.577Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:27:00.577Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "87c5e7b71251d176",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-14T17:27:00.580Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:27:00.580Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f6f08fc0e1e70a11",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "triple-negative breast cancer",
      "analysisTimestamp": "2026-01-14T17:40:25.269Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T17:40:25.269Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "e308381e4a691a50",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "SORAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "SORAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-14T18:00:02.204Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T18:00:02.204Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "1321c47ae76c94a8",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "BINIMETINIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "BINIMETINIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-14T18:00:02.207Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T18:00:02.207Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "6701d611a9f577f0",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DABRAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DABRAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-14T18:00:02.214Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T18:00:02.214Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "ea59aa09490b902c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VEMURAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VEMURAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-14T18:00:02.219Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T18:00:02.219Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "885908a0c297d55e",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-14T18:00:02.228Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T18:00:02.228Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "aa76c8cd14719982",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "SORAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "SORAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-14T19:23:02.568Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T19:23:02.568Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "bf3647b8adaaffbd",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "BINIMETINIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "BINIMETINIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-14T19:23:02.572Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T19:23:02.572Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "7d23e1c2f709f6c9",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DABRAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DABRAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-14T19:23:02.575Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T19:23:02.575Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "39e8df3b8695ebdc",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VEMURAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VEMURAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-14T19:23:02.579Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T19:23:02.579Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "fef1a352429fbfe8",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-14T19:23:02.582Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T19:23:02.582Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "5a4b6c9f082e5662",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "totalScore": 0.8999999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
        "experimentType": "In Vitro Efficacy Testing",
        "protocol": [],
        "controls": [],
        "readouts": [],
        "timeline": "",
        "estimatedCost": "",
        "successCriteria": "",
        "predictedOutcome": ""
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "triple-negative breast cancer",
      "analysisTimestamp": "2026-01-14T19:50:28.256Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T19:50:28.256Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "686b79d22fb9f314",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for triple-negative breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "triple-negative breast cancer",
      "analysisTimestamp": "2026-01-14T21:07:15.598Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T21:07:15.598Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "59b74597a0cfedbe",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for triple-negative breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "triple-negative breast cancer",
      "analysisTimestamp": "2026-01-14T21:39:07.218Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-14T21:39:07.218Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "3e3435060f79748c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for triple-negative breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "triple-negative breast cancer",
      "analysisTimestamp": "2026-01-15T14:07:38.500Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T14:07:38.500Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "06f61a964da8e599",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for triple-negative breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "triple-negative breast cancer",
      "analysisTimestamp": "2026-01-15T14:40:03.069Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T14:40:03.069Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "5ad268fe9df7a949",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PALBOCICLIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PALBOCICLIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with PALBOCICLIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-15T14:45:54.519Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T14:45:54.519Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "3c8241f053d39cfc",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VANDETANIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VANDETANIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with VANDETANIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-15T14:45:54.522Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T14:45:54.522Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "93f16030c274d7fd",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ENTRECTINIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ENTRECTINIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with ENTRECTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-15T14:45:54.524Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T14:45:54.524Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "fee29bde10c4df30",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ADAVOSERTIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8527666666666667,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ADAVOSERTIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with ADAVOSERTIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-15T14:45:54.526Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T14:45:54.526Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "dd39b7e6c6899954",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AST-487 may be repurposed to treat Parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8527666666666667,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AST-487 may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with AST-487 across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-15T14:45:54.528Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T14:45:54.528Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "1add2d791816e6a6",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "SORAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "SORAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with SORAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-15T14:49:46.786Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T14:49:46.786Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "4fbb79e8954ea9fb",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "BINIMETINIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "BINIMETINIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with BINIMETINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-15T14:49:46.789Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T14:49:46.789Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "90168cbe4eddfa7e",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DABRAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DABRAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with DABRAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-15T14:49:46.791Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T14:49:46.791Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "d1ad2e1fe0033a0a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VEMURAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VEMURAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with VEMURAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-15T14:49:46.793Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T14:49:46.793Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "a11b1cabc591623c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with TRAMETINIB DIMETHYL SULFOXIDE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-15T14:49:46.795Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T14:49:46.795Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "2656ab95a9c7bc2c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PALBOCICLIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PALBOCICLIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with PALBOCICLIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-15T15:07:43.513Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T15:07:43.513Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "ff7bfaf817ce5a0e",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VANDETANIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VANDETANIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with VANDETANIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-15T15:07:43.518Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T15:07:43.518Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f23b155d3b0fe50c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ENTRECTINIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ENTRECTINIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with ENTRECTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-15T15:07:43.522Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T15:07:43.522Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "63332d288c61129c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ADAVOSERTIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8527666666666667,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ADAVOSERTIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with ADAVOSERTIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-15T15:07:43.525Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T15:07:43.525Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "bcb726694adabc8a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AST-487 may be repurposed to treat Parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8527666666666667,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AST-487 may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with AST-487 across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-15T15:07:43.531Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T15:07:43.531Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "8b06ac42a6fc1517",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "SORAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "SORAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with SORAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-15T15:34:48.078Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T15:34:48.078Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "9b40c4de3ca78ed0",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "BINIMETINIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "BINIMETINIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with BINIMETINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-15T15:34:48.083Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T15:34:48.083Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "ae5a435607684253",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DABRAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DABRAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with DABRAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-15T15:34:48.087Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T15:34:48.087Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "1e8566082b5feb62",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VEMURAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VEMURAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with VEMURAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-15T15:34:48.092Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T15:34:48.092Z",
      "viewCount": 1,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "2dcc81d836104c86",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with TRAMETINIB DIMETHYL SULFOXIDE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-15T15:34:48.099Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T15:34:48.099Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "ea97f43479db702a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LECANEMAB may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets APOE, APP which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LECANEMAB may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with LECANEMAB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-15T16:00:00.966Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T16:00:00.966Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "9934949adc6c47af",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRIAMCINOLONE may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRIAMCINOLONE may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with TRIAMCINOLONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-15T16:00:00.970Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T16:00:00.970Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "5a5be049c615efa8",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PRAVASTATIN SODIUM may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PRAVASTATIN SODIUM may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with PRAVASTATIN SODIUM across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-15T16:00:00.973Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T16:00:00.973Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "066d13bffdb02c2f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LUTEIN may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LUTEIN may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with LUTEIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-15T16:00:00.978Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T16:00:00.978Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b9564825441b48fd",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "NIROGACESTAT may be repurposed to treat Alzheimer's disease",
      "confidence": 0.836595744680851,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7712340425531914,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8584936170212765,
      "mechanism": "Targets APP, PSEN1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "NIROGACESTAT may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with NIROGACESTAT across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "84% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-15T16:00:00.981Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T16:00:00.981Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "a12565e3fb0eb762",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LECANEMAB may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets APOE, APP which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LECANEMAB may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with LECANEMAB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-15T16:49:27.871Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T16:49:27.871Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f5490edca05068a3",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRIAMCINOLONE may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRIAMCINOLONE may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with TRIAMCINOLONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-15T16:49:27.878Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T16:49:27.878Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "7ff543a5d0be9f89",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PRAVASTATIN SODIUM may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PRAVASTATIN SODIUM may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with PRAVASTATIN SODIUM across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-15T16:49:27.883Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T16:49:27.883Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "ca19d0e2d87e81f9",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LUTEIN may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LUTEIN may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with LUTEIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-15T16:49:27.887Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T16:49:27.887Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "e9b72ba81664185d",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "NIROGACESTAT may be repurposed to treat Alzheimer's disease",
      "confidence": 0.836595744680851,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7712340425531914,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8584936170212765,
      "mechanism": "Targets APP, PSEN1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "NIROGACESTAT may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with NIROGACESTAT across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "84% probability of efficacy"
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-15T16:49:27.893Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T16:49:27.893Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "95c0b4371f674081",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "SORAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "SORAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with SORAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-15T17:21:27.491Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T17:21:27.491Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b422a2016d8e0d0c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "BINIMETINIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "BINIMETINIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with BINIMETINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-15T17:21:27.496Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T17:21:27.496Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "95d65df989f3c192",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DABRAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DABRAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with DABRAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-15T17:21:27.504Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T17:21:27.504Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "c043dda1968cf423",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VEMURAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VEMURAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with VEMURAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-15T17:21:27.507Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T17:21:27.507Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "812c68eca44d7560",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with TRAMETINIB DIMETHYL SULFOXIDE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-15T17:21:27.510Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T17:21:27.510Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "17ce9aa88266a729",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for triple-negative breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "triple-negative breast cancer",
      "analysisTimestamp": "2026-01-15T17:31:24.246Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T17:31:24.246Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "086a9cdc79d05b09",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LECANEMAB may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets APOE, APP which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LECANEMAB may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with LECANEMAB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-15T17:49:21.220Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T17:49:21.220Z",
      "viewCount": 1,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "38fb5f5a13617ad7",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRIAMCINOLONE may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRIAMCINOLONE may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with TRIAMCINOLONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-15T17:49:21.228Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T17:49:21.229Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "ed7ea94c54b36034",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PRAVASTATIN SODIUM may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PRAVASTATIN SODIUM may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with PRAVASTATIN SODIUM across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-15T17:49:21.235Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T17:49:21.235Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "ff84280d62a9224a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LUTEIN may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LUTEIN may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with LUTEIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-15T17:49:21.244Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T17:49:21.244Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "dc0d2a09f412f46c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "NIROGACESTAT may be repurposed to treat Alzheimer's disease",
      "confidence": 0.836595744680851,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7712340425531914,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8584936170212765,
      "mechanism": "Targets APP, PSEN1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "NIROGACESTAT may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with NIROGACESTAT across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "84% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-15T17:49:21.254Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T17:49:21.254Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b15c1a5bbc3d0037",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PALBOCICLIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8984615384615384,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8578461538461539,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8931384615384614,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PALBOCICLIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with PALBOCICLIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-15T19:18:59.405Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:18:59.405Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "a13329da0cab9cfb",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VANDETANIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8984615384615384,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8578461538461539,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8931384615384614,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VANDETANIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with VANDETANIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-15T19:18:59.413Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:18:59.413Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "bceec3bfe87c25cb",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ENTRECTINIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8984615384615384,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8578461538461539,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8931384615384614,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ENTRECTINIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with ENTRECTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-15T19:18:59.416Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:18:59.416Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b2619250c0b1400d",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ADAVOSERTIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8984615384615384,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8578461538461539,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8556384615384616,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ADAVOSERTIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with ADAVOSERTIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-15T19:18:59.422Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:18:59.422Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "aa5286dda7351e45",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AST-487 may be repurposed to treat Parkinson's disease",
      "confidence": 0.8984615384615384,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8578461538461539,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8556384615384616,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AST-487 may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with AST-487 across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-15T19:18:59.429Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:18:59.429Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b81115c5a1e51f59",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T19:22:26.611Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:22:26.611Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "97085fa817111e38",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T19:22:26.615Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:22:26.615Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "90ee02a24e5f96d9",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T19:22:26.619Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:22:26.619Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "be9c83f5a333b547",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T19:22:26.624Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:22:26.624Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "0831690087494c82",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T19:22:26.628Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:22:26.628Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "3914f238a2652707",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LECANEMAB may be repurposed to treat alzheimer's disease",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets APOE, APP which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LECANEMAB may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LECANEMAB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T19:23:21.799Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:23:21.799Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "0071ee90e23e4c1a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with TRIAMCINOLONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T19:23:21.804Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:23:21.804Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "c54ced9ce232d69c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with PRAVASTATIN SODIUM across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T19:23:21.808Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:23:21.808Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "4836ac325ac84f30",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LUTEIN may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LUTEIN may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LUTEIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T19:23:21.814Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:23:21.814Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "95bb1d6cbb6b4ae3",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
      "confidence": 0.836595744680851,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7712340425531914,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8584936170212765,
      "mechanism": "Targets APP, PSEN1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with NIROGACESTAT across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "84% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T19:23:21.819Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:23:21.819Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "9b590cb40cf002e3",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets DNMT3A, FLT3, NPM1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DAUNORUBICIN LIPOSOMAL across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T19:24:05.633Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:24:05.633Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b3560a7accb55c2f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with AZACITIDINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T19:24:05.654Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:24:05.654Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "47359a6f911c967c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with QUIZARTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T19:24:05.685Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:24:05.685Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "eec82a9a8b0acd12",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DECITABINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DECITABINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DECITABINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T19:24:05.711Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:24:05.711Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f7148f76dfee1986",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with IDARUBICIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T19:24:05.731Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:24:05.731Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "e38220dfa46a70f4",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PALBOCICLIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PALBOCICLIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with PALBOCICLIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T19:24:52.605Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:24:52.605Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b1a7e4ce1372b37f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VANDETANIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VANDETANIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with VANDETANIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T19:24:52.614Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:24:52.614Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "05454d84f8d6d2b3",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ENTRECTINIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ENTRECTINIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ENTRECTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T19:24:52.621Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:24:52.621Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "10a38f185a9f4aee",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8527666666666667,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ADAVOSERTIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T19:24:52.628Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:24:52.628Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "fc3601e52bcb7d06",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AST-487 may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8527666666666667,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AST-487 may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with AST-487 across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T19:24:52.635Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:24:52.635Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "bb1c124910ce9d3f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "REGORAFENIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets EGFR, PDGFRA, PTEN which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PDGFRA",
          "description": "Drug targets gene associated with disease",
          "weight": 0.37
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PDGFRA",
          "description": "Drug targets gene associated with disease",
          "weight": 0.37
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "REGORAFENIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with REGORAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T19:25:41.332Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:25:41.332Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "39ddf26f7f6bba00",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T19:25:41.339Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:25:41.339Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b663ede58045eb20",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T19:25:41.346Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:25:41.346Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "3540572547298e1a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T19:25:41.352Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:25:41.352Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "950ff94cc0e4668d",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T19:25:41.358Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:25:41.358Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "8235cdf5544d2d1f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "METFORMIN may be repurposed to treat type 2 diabetes",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets PPARG, TCF7L2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "METFORMIN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with METFORMIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T19:26:31.195Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:26:31.195Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "c1182c1c9717bfcf",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8879999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8432,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8872799999999998,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with TROGLITAZONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T19:26:31.204Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:26:31.204Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "1f6a85a27af4f049",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8879999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8432,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8872799999999998,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with ESTRADIOL VALERATE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T19:26:31.211Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:26:31.211Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "653f66e750996b30",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GLYBURIDE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8879999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8432,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8872799999999998,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GLYBURIDE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with GLYBURIDE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T19:26:31.221Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:26:31.221Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "15c7057f6b971144",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
      "confidence": 0.856,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7984000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.86936,
      "mechanism": "Targets PPARG which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with PROPYLPARABEN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T19:26:31.229Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:26:31.229Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "e2e925aa5af0f0b7",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "SORAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "SORAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with SORAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-15T19:42:35.118Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:42:35.118Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "8e29c8674e173d7f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "BINIMETINIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "BINIMETINIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with BINIMETINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-15T19:42:35.124Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:42:35.124Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "9e570e3812fb827d",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DABRAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DABRAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with DABRAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-15T19:42:35.132Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:42:35.132Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "4fec0c26de6b9fc4",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VEMURAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VEMURAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with VEMURAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-15T19:42:35.138Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:42:35.138Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "57baa54002801299",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with TRAMETINIB DIMETHYL SULFOXIDE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-15T19:42:35.146Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:42:35.146Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "a97e7e114fd6babc",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T19:43:55.278Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:43:55.278Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "122616917e351aaa",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T19:43:55.285Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:43:55.285Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "5bbf770fef25462d",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T19:43:55.293Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:43:55.293Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "4f3ae0a8ee903fe6",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T19:43:55.298Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:43:55.298Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "2a1e748cd65819c8",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T19:43:55.305Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:43:55.305Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "9c56ecdc47ef13e5",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LECANEMAB may be repurposed to treat alzheimer's disease",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets APOE, APP which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LECANEMAB may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LECANEMAB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T19:46:19.103Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:46:19.103Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "623c1436020a6b47",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with TRIAMCINOLONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T19:46:19.113Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:46:19.113Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "e4c212ca5d60d196",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with PRAVASTATIN SODIUM across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T19:46:19.122Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:46:19.122Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "7be55005e9d8425c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LUTEIN may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LUTEIN may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LUTEIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T19:46:19.129Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:46:19.129Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "e9a199d7c8da732f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
      "confidence": 0.836595744680851,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7712340425531914,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8584936170212765,
      "mechanism": "Targets APP, PSEN1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with NIROGACESTAT across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "84% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T19:46:19.137Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:46:19.137Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "abfaa7a59b5340af",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets DNMT3A, FLT3, NPM1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DAUNORUBICIN LIPOSOMAL across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T19:46:59.973Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:46:59.973Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "6563b26b8271c4a2",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with AZACITIDINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T19:46:59.980Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:46:59.980Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "403c9df15fa8aa49",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with QUIZARTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T19:46:59.988Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:46:59.988Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "eac023f6a2a431f5",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DECITABINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DECITABINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DECITABINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T19:46:59.995Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:46:59.995Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "5295ddad41931b72",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with IDARUBICIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T19:47:00.004Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:47:00.004Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "393664e33e7b0367",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PALBOCICLIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PALBOCICLIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with PALBOCICLIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T19:47:49.452Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:47:49.452Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "e79dfa6aae49897c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VANDETANIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VANDETANIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with VANDETANIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T19:47:49.464Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:47:49.464Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "3d257bfd22ce8c15",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ENTRECTINIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ENTRECTINIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ENTRECTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T19:47:49.474Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:47:49.474Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b965dbd4080b82d4",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8527666666666667,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ADAVOSERTIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T19:47:49.485Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:47:49.485Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "64f09b6593472c25",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AST-487 may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8527666666666667,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AST-487 may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with AST-487 across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T19:47:49.495Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:47:49.495Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f73a92dcc1642c8d",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "REGORAFENIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets EGFR, PDGFRA, PTEN which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PDGFRA",
          "description": "Drug targets gene associated with disease",
          "weight": 0.37
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PDGFRA",
          "description": "Drug targets gene associated with disease",
          "weight": 0.37
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "REGORAFENIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with REGORAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T19:48:34.420Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:48:34.420Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "bfb4d3802476bddf",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T19:48:34.430Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:48:34.430Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "fefb9c2203c9701e",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T19:48:34.439Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:48:34.439Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "6ba8c662cdeab090",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T19:48:34.449Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:48:34.449Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "506760145769290b",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T19:48:34.458Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:48:34.458Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "d9ab6b6ad1a64f60",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "METFORMIN may be repurposed to treat type 2 diabetes",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets PPARG, TCF7L2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "METFORMIN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with METFORMIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T19:49:23.213Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:49:23.213Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "74b8f57d9667701f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8799999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8319999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8828,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with TROGLITAZONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T19:49:23.224Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:49:23.224Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "c940d2acc588c78a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8799999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8319999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8828,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with ESTRADIOL VALERATE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T19:49:23.232Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:49:23.232Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "a285483599cfc557",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GLYBURIDE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8799999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8319999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8828,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GLYBURIDE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with GLYBURIDE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T19:49:23.242Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:49:23.242Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "0d6c56e2e0be0619",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
      "confidence": 0.856,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7984000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.86936,
      "mechanism": "Targets PPARG which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with PROPYLPARABEN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T19:49:23.250Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:49:23.250Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "7246a6977a9c7a29",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T19:57:07.345Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:57:07.345Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "31a2d4642f607e5c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T19:57:07.359Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:57:07.359Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "0f4f47cdd8f0b70a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T19:57:07.371Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:57:07.371Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "1665b9e776340c58",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T19:57:07.379Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:57:07.379Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "665a31e8fb245c99",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T19:57:07.388Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:57:07.388Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "9ed54974f919de37",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LECANEMAB may be repurposed to treat alzheimer's disease",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets APOE, APP which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LECANEMAB may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LECANEMAB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T19:59:26.581Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:59:26.581Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "041692515b8f33a3",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with TRIAMCINOLONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T19:59:26.593Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:59:26.593Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "9626ecf0a5ab067e",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with PRAVASTATIN SODIUM across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T19:59:26.604Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:59:26.604Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "72ed41dbda1b824b",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LUTEIN may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LUTEIN may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LUTEIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T19:59:26.613Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:59:26.614Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "435018130793d4c7",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
      "confidence": 0.836595744680851,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7712340425531914,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8584936170212765,
      "mechanism": "Targets APP, PSEN1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with NIROGACESTAT across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "84% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T19:59:26.625Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T19:59:26.626Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "aa742c9210c6458c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets DNMT3A, FLT3, NPM1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DAUNORUBICIN LIPOSOMAL across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:00:00.217Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:00:00.217Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "612826d61869e5c1",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with AZACITIDINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:00:00.226Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:00:00.226Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "6de0402594b7d0d5",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with QUIZARTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:00:00.236Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:00:00.236Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "24a478c369bf1772",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DECITABINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DECITABINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DECITABINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:00:00.246Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:00:00.246Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "5eaa640670abeab2",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with IDARUBICIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:00:00.259Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:00:00.259Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "88784798ec663cd7",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PALBOCICLIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8885714285714286,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8440000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8876,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PALBOCICLIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with PALBOCICLIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:00:50.095Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:00:50.095Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "d42c21fe5550e12b",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VANDETANIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8885714285714286,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8440000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8876,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VANDETANIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with VANDETANIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:00:50.106Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:00:50.106Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "49af77c4d0643830",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ENTRECTINIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8885714285714286,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8440000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8876,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ENTRECTINIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ENTRECTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:00:50.117Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:00:50.117Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "d5bff4e6680bb27b",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8885714285714286,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8440000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8501000000000001,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ADAVOSERTIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:00:50.126Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:00:50.126Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f144eadf0403d95d",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AST-487 may be repurposed to treat parkinson's disease",
      "confidence": 0.8885714285714286,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8440000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8501000000000001,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AST-487 may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with AST-487 across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:00:50.136Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:00:50.136Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "057e4953de8176db",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "REGORAFENIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets EGFR, PDGFRA, PTEN which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PDGFRA",
          "description": "Drug targets gene associated with disease",
          "weight": 0.37
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PDGFRA",
          "description": "Drug targets gene associated with disease",
          "weight": 0.37
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "REGORAFENIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with REGORAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:01:36.229Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:01:36.229Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "13772bfdbe22c84b",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:01:36.242Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:01:36.242Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "68ef876e7910f3ad",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:01:36.254Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:01:36.254Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "085141d99babadec",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:01:36.265Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:01:36.265Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "38be2ab474ff6df0",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:01:36.277Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:01:36.277Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "7042dbef9a586703",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "METFORMIN may be repurposed to treat type 2 diabetes",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets PPARG, TCF7L2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "METFORMIN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with METFORMIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:02:25.394Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:02:25.394Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "c5698e01f32fea31",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8799999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8319999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8828,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with TROGLITAZONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:02:25.409Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:02:25.409Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "a1897cc51e1d66b3",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8799999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8319999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8828,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with ESTRADIOL VALERATE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:02:25.422Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:02:25.422Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b6fbc543a7e2d7f7",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GLYBURIDE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8799999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8319999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8828,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GLYBURIDE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with GLYBURIDE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:02:25.433Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:02:25.433Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "046532dc058c499a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
      "confidence": 0.856,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7984000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.86936,
      "mechanism": "Targets PPARG which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with PROPYLPARABEN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:02:25.446Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:02:25.446Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "25196ed51a043b10",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T20:05:31.030Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:05:31.030Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "396d38cb7b1fee20",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T20:05:31.038Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:05:31.038Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "241d8c631350632d",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T20:05:31.047Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:05:31.047Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f60ce7c23a9c78ca",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T20:05:31.055Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:05:31.055Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "dbd561002c88edaf",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T20:05:31.063Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:05:31.063Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "04e4acdc5eec6976",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LECANEMAB may be repurposed to treat alzheimer's disease",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets APOE, APP which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LECANEMAB may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LECANEMAB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T20:08:17.609Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:08:17.609Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "4a9b76acd54ef905",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with TRIAMCINOLONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T20:08:17.627Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:08:17.627Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "2b9c30fecaa7e6cb",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with PRAVASTATIN SODIUM across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T20:08:17.642Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:08:17.642Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "ca7b054c8fc47455",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LUTEIN may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LUTEIN may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LUTEIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T20:08:17.659Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:08:17.659Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "a8039d29c0336f5a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
      "confidence": 0.836595744680851,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7712340425531914,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8584936170212765,
      "mechanism": "Targets APP, PSEN1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with NIROGACESTAT across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "84% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T20:08:17.675Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:08:17.675Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "d03ee11467781e03",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets DNMT3A, FLT3, NPM1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DAUNORUBICIN LIPOSOMAL across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:09:39.075Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:09:39.075Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "7bbaae6bf9ec3000",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with AZACITIDINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:09:39.093Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:09:39.093Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "afe0d5f2774603ea",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with QUIZARTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:09:39.110Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:09:39.110Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "d0b2a4b33a25f6e7",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DECITABINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DECITABINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DECITABINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:09:39.128Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:09:39.128Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "16c518bdc23f1d1a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with IDARUBICIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:09:39.144Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:09:39.144Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f60c6651bf21728c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PALBOCICLIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PALBOCICLIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with PALBOCICLIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:10:37.788Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:10:37.788Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "6dd674b174c3f79f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VANDETANIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VANDETANIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with VANDETANIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:10:37.802Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:10:37.802Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "8d444d6f2f94b7be",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ENTRECTINIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ENTRECTINIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ENTRECTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:10:37.817Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:10:37.817Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "790b439d7cbcefe5",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8527666666666667,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ADAVOSERTIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:10:37.830Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:10:37.830Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "0a79cf1aad3e8b48",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AST-487 may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8527666666666667,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AST-487 may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with AST-487 across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:10:37.843Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:10:37.843Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "8ef5240d68758aa6",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "REGORAFENIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets EGFR, PDGFRA, PTEN which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PDGFRA",
          "description": "Drug targets gene associated with disease",
          "weight": 0.37
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PDGFRA",
          "description": "Drug targets gene associated with disease",
          "weight": 0.37
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "REGORAFENIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with REGORAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:11:20.615Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:11:20.615Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "835f543751b4ec2d",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:11:20.628Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:11:20.628Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "c4a2ba2d69a46a4e",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:11:20.644Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:11:20.644Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "db46442cbdf22546",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:11:20.658Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:11:20.658Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "6c58880479b8be67",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:11:20.675Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:11:20.675Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "81069eba5180fc50",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "METFORMIN may be repurposed to treat type 2 diabetes",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets PPARG, TCF7L2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "METFORMIN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with METFORMIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:12:16.547Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:12:16.547Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "228fa367558dd4f1",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8879999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8432,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8872799999999998,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with TROGLITAZONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:12:16.560Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:12:16.560Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "9005da504b589714",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8879999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8432,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8872799999999998,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with ESTRADIOL VALERATE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:12:16.577Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:12:16.577Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "9064ab37132a39ab",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GLYBURIDE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8879999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8432,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8872799999999998,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GLYBURIDE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with GLYBURIDE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:12:16.594Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:12:16.594Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "30412b1a63f0afff",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
      "confidence": 0.856,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7984000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.86936,
      "mechanism": "Targets PPARG which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with PROPYLPARABEN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:12:16.610Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:12:16.610Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "74dde69eb95cdeb5",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T20:25:10.244Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:25:10.244Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "2784d69e370042cd",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T20:25:10.259Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:25:10.259Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "3ba1c2383e0f2370",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T20:25:10.270Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:25:10.270Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "959fdbf9b7828ca8",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T20:25:10.283Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:25:10.283Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "c7eaff998a855854",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T20:25:10.297Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:25:10.297Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "eadf76a0fd85c616",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LECANEMAB may be repurposed to treat alzheimer's disease",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets APOE, APP which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LECANEMAB may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LECANEMAB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T20:27:33.615Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:27:33.615Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f26e420ae995de88",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with TRIAMCINOLONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T20:27:33.628Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:27:33.628Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "1bf8a6fca137a6b3",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with PRAVASTATIN SODIUM across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T20:27:33.640Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:27:33.640Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "ab6ea174e4fd6124",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LUTEIN may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LUTEIN may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LUTEIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T20:27:33.652Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:27:33.652Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "830cad6f8abc9dd9",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
      "confidence": 0.836595744680851,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7712340425531914,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8584936170212765,
      "mechanism": "Targets APP, PSEN1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with NIROGACESTAT across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "84% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T20:27:33.665Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:27:33.665Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "d96db65da1b74c59",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets DNMT3A, FLT3, NPM1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DAUNORUBICIN LIPOSOMAL across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:28:08.322Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:28:08.322Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f92e54a602569e24",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with AZACITIDINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:28:08.335Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:28:08.335Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "169df88c8eb6bff3",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with QUIZARTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:28:08.346Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:28:08.346Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "db707ad4ad95b4c7",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DECITABINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DECITABINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DECITABINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:28:08.360Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:28:08.360Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "5bd461f191d791d5",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with IDARUBICIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:28:08.372Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:28:08.372Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "89c06e62cd61bd83",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PALBOCICLIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8885714285714286,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8440000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8876,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PALBOCICLIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with PALBOCICLIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:28:57.720Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:28:57.720Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "5daa27f44bcd2b93",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VANDETANIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8885714285714286,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8440000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8876,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VANDETANIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with VANDETANIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:28:57.737Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:28:57.737Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "30a4806de2028625",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ENTRECTINIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8885714285714286,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8440000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8876,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ENTRECTINIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ENTRECTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:28:57.750Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:28:57.750Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "eac75bf0dfec55e4",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8885714285714286,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8440000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8501000000000001,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ADAVOSERTIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:28:57.763Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:28:57.763Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f8876a87c08e8a8a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AST-487 may be repurposed to treat parkinson's disease",
      "confidence": 0.8885714285714286,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8440000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8501000000000001,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AST-487 may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with AST-487 across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:28:57.774Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:28:57.774Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "da50955defe7c4ac",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "REGORAFENIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets EGFR, PDGFRA, PTEN which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PDGFRA",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "REGORAFENIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with REGORAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:29:35.772Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:29:35.772Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "032c7cf65b0d7d95",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:29:35.785Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:29:35.785Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "641a30c4e0d13d6c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:29:35.800Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:29:35.800Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "590e83886790e9cc",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:29:35.815Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:29:35.815Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "9aac8492944a6b0e",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:29:35.829Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:29:35.829Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "efab76dc7704d56d",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "METFORMIN may be repurposed to treat type 2 diabetes",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets PPARG, TCF7L2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "METFORMIN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with METFORMIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:30:19.571Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:30:19.571Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f4161b34fc09d22e",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8879999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8432,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8872799999999998,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with TROGLITAZONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:30:19.586Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:30:19.586Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "907a61449d1257a7",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8879999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8432,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8872799999999998,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with ESTRADIOL VALERATE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:30:19.602Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:30:19.602Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "d742830c2f840759",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GLYBURIDE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8879999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8432,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8872799999999998,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GLYBURIDE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with GLYBURIDE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:30:19.617Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:30:19.617Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "49172e05739c9323",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
      "confidence": 0.856,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7984000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.86936,
      "mechanism": "Targets PPARG which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with PROPYLPARABEN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:30:19.633Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:30:19.633Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "5fb5ce18ec7c2c02",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T20:32:24.200Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:32:24.200Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f8ee75cf508ccc73",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T20:32:24.213Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:32:24.213Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f509aff5affe3f50",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T20:32:24.225Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:32:24.225Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "c03e8ca5eb0bec5e",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T20:32:24.237Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:32:24.237Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "75ed8b96496ed67b",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T20:32:24.249Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:32:24.249Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "926a55eeff8cb701",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LECANEMAB may be repurposed to treat alzheimer's disease",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets APOE, APP which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LECANEMAB may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LECANEMAB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T20:34:52.896Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:34:52.896Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "859b24b7e7229de2",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with TRIAMCINOLONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T20:34:52.911Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:34:52.911Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "2dd289ea982d2ac8",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with PRAVASTATIN SODIUM across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T20:34:52.925Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:34:52.925Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "ec0fc2d432c8bd8e",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LUTEIN may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LUTEIN may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LUTEIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T20:34:52.940Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:34:52.940Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "11aefc48f2fc3c28",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
      "confidence": 0.836595744680851,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7712340425531914,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8584936170212765,
      "mechanism": "Targets APP, PSEN1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with NIROGACESTAT across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "84% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T20:34:52.955Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:34:52.955Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "28c624ba55742c51",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets DNMT3A, FLT3, NPM1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DAUNORUBICIN LIPOSOMAL across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:35:26.286Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:35:26.286Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "55a8365e7e72569b",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with AZACITIDINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:35:26.304Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:35:26.304Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f55025017d05697f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with QUIZARTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:35:26.318Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:35:26.318Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "878028b510e2ee6c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DECITABINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DECITABINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DECITABINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:35:26.337Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:35:26.337Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "8d5be2836aaa8366",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with IDARUBICIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:35:26.353Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:35:26.353Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "6ba973f65e8905df",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PALBOCICLIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8885714285714286,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8440000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8876,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PALBOCICLIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with PALBOCICLIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:36:14.342Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:36:14.342Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "8ce58e5355538cf2",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VANDETANIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8885714285714286,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8440000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8876,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VANDETANIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with VANDETANIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:36:14.360Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:36:14.360Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "eba46226138ea173",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ENTRECTINIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8885714285714286,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8440000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8876,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ENTRECTINIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ENTRECTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:36:14.377Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:36:14.377Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "113d6f0c50915fb1",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8885714285714286,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8440000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8501000000000001,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ADAVOSERTIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:36:14.392Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:36:14.392Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "d0e1407284f00820",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AST-487 may be repurposed to treat parkinson's disease",
      "confidence": 0.8885714285714286,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8440000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8501000000000001,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AST-487 may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with AST-487 across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:36:14.409Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:36:14.409Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f05693a9f418fad2",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "REGORAFENIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets EGFR, PDGFRA, PTEN which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PDGFRA",
          "description": "Drug targets gene associated with disease",
          "weight": 0.37
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PDGFRA",
          "description": "Drug targets gene associated with disease",
          "weight": 0.37
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "REGORAFENIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with REGORAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:36:49.928Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:36:49.928Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "a3ad70706804fc1a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:36:49.942Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:36:49.942Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "c1557c6ff3bcf8ca",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:36:49.956Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:36:49.956Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "2f9abed410b6734f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:36:49.969Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:36:49.969Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "65036d7412be130c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:36:49.982Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:36:49.982Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b6ea909ed84ba546",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "METFORMIN may be repurposed to treat type 2 diabetes",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets PPARG, TCF7L2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "METFORMIN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with METFORMIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:37:32.519Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:37:32.519Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "ebf4cab8a15d3d69",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8799999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8319999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8828,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with TROGLITAZONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:37:32.533Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:37:32.533Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "6b399c5b256f0bb9",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8799999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8319999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8828,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with ESTRADIOL VALERATE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:37:32.547Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:37:32.547Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "25dedde813ec419b",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GLYBURIDE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8799999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8319999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8828,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GLYBURIDE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with GLYBURIDE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:37:32.562Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:37:32.562Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "5a75c1e6750282b4",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
      "confidence": 0.856,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7984000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.86936,
      "mechanism": "Targets PPARG which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with PROPYLPARABEN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:37:32.576Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:37:32.576Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b0ec85db75ecd849",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T20:39:47.039Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:39:47.039Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b57477a316304a0f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T20:39:47.053Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:39:47.053Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "13cfa143db839587",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T20:39:47.067Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:39:47.067Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "90f7034cb47cfe5e",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T20:39:47.081Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:39:47.081Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "fa1c0885c5529913",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T20:39:47.094Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:39:47.094Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "5526be2161391b52",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LECANEMAB may be repurposed to treat alzheimer's disease",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets APOE, APP which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LECANEMAB may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LECANEMAB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T20:42:00.272Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:42:00.272Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "1f9276c8f628fc42",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with TRIAMCINOLONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T20:42:00.287Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:42:00.287Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b48531f94f2b4cf0",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with PRAVASTATIN SODIUM across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T20:42:00.301Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:42:00.301Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f8de93557af63ebf",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LUTEIN may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LUTEIN may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LUTEIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T20:42:00.315Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:42:00.315Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "aaee9fcc52993b97",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
      "confidence": 0.836595744680851,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7712340425531914,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8584936170212765,
      "mechanism": "Targets APP, PSEN1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with NIROGACESTAT across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "84% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T20:42:00.331Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:42:00.331Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b949b030fb38e096",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets DNMT3A, FLT3, NPM1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DAUNORUBICIN LIPOSOMAL across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:42:37.682Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:42:37.682Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "7972a3cad4dce633",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with AZACITIDINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:42:37.700Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:42:37.700Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "ec2c5736f689d7a5",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with QUIZARTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:42:37.717Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:42:37.717Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "4cfcc4f77c6db4fb",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DECITABINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DECITABINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DECITABINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:42:37.738Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:42:37.738Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "19e990b150405955",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with IDARUBICIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T20:42:37.757Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:42:37.757Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "0b02818ed1413d6a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PALBOCICLIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PALBOCICLIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with PALBOCICLIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:43:23.817Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:43:23.817Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "5b2f572295cc1c01",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VANDETANIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VANDETANIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with VANDETANIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:43:23.839Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:43:23.839Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f357a26ed1ecebf1",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ENTRECTINIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ENTRECTINIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ENTRECTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:43:23.858Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:43:23.858Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "e77b5d4109248aa2",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8527666666666667,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ADAVOSERTIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:43:23.877Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:43:23.877Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "67335589aa73db07",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AST-487 may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8527666666666667,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AST-487 may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with AST-487 across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T20:43:23.896Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:43:23.896Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "d7c463f48eadcb53",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "REGORAFENIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets EGFR, PDGFRA, PTEN which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PDGFRA",
          "description": "Drug targets gene associated with disease",
          "weight": 0.37
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PDGFRA",
          "description": "Drug targets gene associated with disease",
          "weight": 0.37
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "REGORAFENIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with REGORAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:44:09.385Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:44:09.385Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "06dcd0f65693f4b8",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:44:09.404Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:44:09.404Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b091b9ef16741604",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:44:09.423Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:44:09.423Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "315ded6a60c1afc0",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:44:09.444Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:44:09.444Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "379cc0431f7ccf75",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T20:44:09.462Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:44:09.463Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "8354554a4e8bbfa9",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "METFORMIN may be repurposed to treat type 2 diabetes",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets PPARG, TCF7L2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "METFORMIN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with METFORMIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:44:51.542Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:44:51.542Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "4bef251b26df57cb",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8879999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8432,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8872799999999998,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with TROGLITAZONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:44:51.557Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:44:51.557Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "4e3de59b857f2742",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8879999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8432,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8872799999999998,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with ESTRADIOL VALERATE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:44:51.572Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:44:51.572Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "4b9df9538462363c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GLYBURIDE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8879999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8432,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8872799999999998,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GLYBURIDE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with GLYBURIDE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:44:51.587Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:44:51.587Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b7911b17c9f57360",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
      "confidence": 0.856,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7984000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.86936,
      "mechanism": "Targets PPARG which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with PROPYLPARABEN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T20:44:51.602Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T20:44:51.602Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "74bf2d8c950af514",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T21:13:41.502Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:13:41.502Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "44c64012b2f5cf7f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T21:13:41.516Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:13:41.516Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "40b7e731c7708052",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T21:13:41.533Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:13:41.533Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "d90420021767237b",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T21:13:41.548Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:13:41.548Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "5d6f865e48542087",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T21:13:41.563Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:13:41.563Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "7db1f41a76bf587e",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LECANEMAB may be repurposed to treat alzheimer's disease",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets APOE, APP which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LECANEMAB may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LECANEMAB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T21:16:18.253Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:16:18.253Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "07764c819198e0c8",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with TRIAMCINOLONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T21:16:18.271Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:16:18.271Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "14b8bf4fc6f1883b",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with PRAVASTATIN SODIUM across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T21:16:18.287Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:16:18.287Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "da715fd134d56f90",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LUTEIN may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LUTEIN may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LUTEIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T21:16:18.307Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:16:18.307Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "1c919a88c8c7e416",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
      "confidence": 0.836595744680851,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7712340425531914,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8584936170212765,
      "mechanism": "Targets APP, PSEN1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with NIROGACESTAT across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "84% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T21:16:18.329Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:16:18.329Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "1b58d2f52108e96e",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets DNMT3A, FLT3, NPM1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DAUNORUBICIN LIPOSOMAL across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T21:16:47.523Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:16:47.523Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "7022f99bce9e2693",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with AZACITIDINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T21:16:47.539Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:16:47.539Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "4dfff9cdffee13df",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with QUIZARTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T21:16:47.554Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:16:47.554Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "8ce069c910d80c86",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DECITABINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DECITABINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DECITABINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T21:16:47.571Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:16:47.571Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "8a7ff51eaf259620",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with IDARUBICIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T21:16:47.588Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:16:47.588Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "5db1179cee08010c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PALBOCICLIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PALBOCICLIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with PALBOCICLIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T21:17:37.485Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:17:37.485Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "28f0eeb4471f7f05",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VANDETANIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VANDETANIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with VANDETANIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T21:17:37.505Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:17:37.505Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "d57649e12a120e46",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ENTRECTINIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ENTRECTINIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ENTRECTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T21:17:37.525Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:17:37.525Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "d0ea029e1da509cc",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8527666666666667,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ADAVOSERTIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T21:17:37.546Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:17:37.546Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "ee26158f632c56c1",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AST-487 may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8527666666666667,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AST-487 may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with AST-487 across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T21:17:37.565Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:17:37.565Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "54d143c5903c7c54",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "REGORAFENIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets EGFR, PDGFRA, PTEN which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PDGFRA",
          "description": "Drug targets gene associated with disease",
          "weight": 0.37
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PDGFRA",
          "description": "Drug targets gene associated with disease",
          "weight": 0.37
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "REGORAFENIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with REGORAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T21:18:17.708Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:18:17.708Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "01843e7aa3bb8066",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T21:18:17.727Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:18:17.727Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "fbdcdb15e36cdf6a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T21:18:17.743Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:18:17.743Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f2a668894b117c91",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T21:18:17.760Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:18:17.760Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f5bd6e3d2971a2e6",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T21:18:17.784Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:18:17.784Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "ace151c829598966",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "METFORMIN may be repurposed to treat type 2 diabetes",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets PPARG, TCF7L2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "METFORMIN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with METFORMIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T21:19:01.853Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:19:01.853Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "5a1d779ad15b7501",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8879999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8432,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8872799999999998,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with TROGLITAZONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T21:19:01.873Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:19:01.873Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b66a54739b55cd4a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8879999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8432,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8872799999999998,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with ESTRADIOL VALERATE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T21:19:01.892Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:19:01.892Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "87b4ecac56db6f14",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GLYBURIDE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8879999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8432,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8872799999999998,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GLYBURIDE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with GLYBURIDE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T21:19:01.910Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:19:01.910Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "76cd87151bd89e2b",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
      "confidence": 0.856,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7984000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.86936,
      "mechanism": "Targets PPARG which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with PROPYLPARABEN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T21:19:01.929Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T21:19:01.929Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "954681b097c82f2e",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T22:59:21.541Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T22:59:21.541Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "361dd150da4d1340",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
      "confidence": 0.7533333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.7346666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.7863666666666665,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "75% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T22:59:21.560Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T22:59:21.560Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "c502c240336dc4d3",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat breast cancer",
      "confidence": 0.7533333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.7346666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.7863666666666665,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "75% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T22:59:21.579Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T22:59:21.579Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "0d784098fcc2b3c1",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat breast cancer",
      "confidence": 0.7533333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.7346666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.7863666666666665,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "75% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T22:59:21.599Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T22:59:21.599Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "1cac11b56c872021",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat breast cancer",
      "confidence": 0.7533333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.7346666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.7863666666666665,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "75% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T22:59:21.618Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T22:59:21.618Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "bb7c3f8fc6be4925",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LECANEMAB may be repurposed to treat alzheimer's disease",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets APOE, APP which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LECANEMAB may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LECANEMAB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T23:01:27.732Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:01:27.732Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "2c4a7b34e7ceb839",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with TRIAMCINOLONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T23:01:27.752Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:01:27.752Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "7737f3e12893273b",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with PRAVASTATIN SODIUM across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T23:01:27.771Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:01:27.771Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "0f67ba0d8b46e29d",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LUTEIN may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LUTEIN may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LUTEIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T23:01:27.792Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:01:27.792Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b2666dee925e4e67",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
      "confidence": 0.836595744680851,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7712340425531914,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8584936170212765,
      "mechanism": "Targets APP, PSEN1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with NIROGACESTAT across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "84% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T23:01:27.816Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:01:27.816Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "0d0a67db5c031009",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets DNMT3A, FLT3, NPM1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DAUNORUBICIN LIPOSOMAL across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T23:02:09.977Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:02:09.977Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "3ed1c510f640f1b5",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with AZACITIDINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T23:02:10.001Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:02:10.001Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "56bd066ba69b5286",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with QUIZARTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T23:02:10.021Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:02:10.021Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "524dc19b932a4a62",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DECITABINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DECITABINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DECITABINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T23:02:10.041Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:02:10.041Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "66b80cd21ecaae8b",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with IDARUBICIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T23:02:10.059Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:02:10.059Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "eb6ba78aa77db737",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PALBOCICLIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PALBOCICLIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with PALBOCICLIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T23:03:11.156Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:03:11.156Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "605497f26eb71fcb",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VANDETANIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VANDETANIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with VANDETANIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T23:03:11.181Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:03:11.181Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "a01ab3d2b97188d9",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ENTRECTINIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ENTRECTINIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ENTRECTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T23:03:11.206Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:03:11.206Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "69fce29eb7964e55",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8527666666666667,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ADAVOSERTIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T23:03:11.226Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:03:11.226Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "19e59fcb15c97cdb",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AST-487 may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8527666666666667,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AST-487 may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with AST-487 across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T23:03:11.248Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:03:11.248Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "a29e9f28e4d58742",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "REGORAFENIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets EGFR, PDGFRA, PTEN which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PDGFRA",
          "description": "Drug targets gene associated with disease",
          "weight": 0.37
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PDGFRA",
          "description": "Drug targets gene associated with disease",
          "weight": 0.37
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "REGORAFENIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with REGORAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T23:03:44.890Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:03:44.890Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "ee8ec1933a8d817c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T23:03:44.912Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:03:44.912Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "85eb68232a3823f2",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T23:03:44.935Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:03:44.935Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "93a9ab9767597c44",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T23:03:44.958Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:03:44.958Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "6720390959ee3c6b",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T23:03:44.979Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:03:44.979Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "4b497e115c94b517",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "METFORMIN may be repurposed to treat type 2 diabetes",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets PPARG, TCF7L2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "METFORMIN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with METFORMIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T23:04:41.068Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:04:41.068Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "46a3d9f5d6c9e781",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8799999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8319999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8828,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with TROGLITAZONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T23:04:41.092Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:04:41.092Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "2ca40062d5144bf4",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8799999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8319999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8828,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with ESTRADIOL VALERATE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T23:04:41.115Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:04:41.115Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "6507afe787c4c96d",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GLYBURIDE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8799999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8319999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8828,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GLYBURIDE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with GLYBURIDE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T23:04:41.135Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:04:41.135Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "e1a13a09531167ca",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
      "confidence": 0.856,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7984000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.86936,
      "mechanism": "Targets PPARG which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with PROPYLPARABEN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T23:04:41.165Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:04:41.165Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "9b314ff44a96e8c6",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T23:07:30.484Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:07:30.484Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "89d575df66d5ed82",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T23:07:30.506Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:07:30.506Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "9dd5a02d533040aa",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T23:07:30.532Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:07:30.532Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "53306cf42aa66447",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T23:07:30.555Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:07:30.555Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "e15a06690e00c169",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-15T23:07:30.580Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:07:30.580Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b8ce06dfd372572f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LECANEMAB may be repurposed to treat alzheimer's disease",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets APOE, APP which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LECANEMAB may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LECANEMAB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T23:08:41.529Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:08:41.529Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "18e833fc59cd7ae2",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with TRIAMCINOLONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T23:08:41.550Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:08:41.550Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "9fd74fa3004f13d1",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with PRAVASTATIN SODIUM across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T23:08:41.572Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:08:41.572Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "e849f140cd781789",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LUTEIN may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LUTEIN may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LUTEIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T23:08:41.594Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:08:41.594Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "e799a613aed77055",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
      "confidence": 0.836595744680851,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7712340425531914,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8584936170212765,
      "mechanism": "Targets APP, PSEN1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with NIROGACESTAT across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "84% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-15T23:08:41.619Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:08:41.619Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "ba713f11b8313037",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets DNMT3A, FLT3, NPM1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DAUNORUBICIN LIPOSOMAL across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T23:09:20.598Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:09:20.598Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "7998a982a8977f83",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with AZACITIDINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T23:09:20.624Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:09:20.624Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "a4c498fe147a74c9",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with QUIZARTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T23:09:20.650Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:09:20.650Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "d6929e343f9a8fb5",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DECITABINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DECITABINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DECITABINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T23:09:20.675Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:09:20.675Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "c662093fec31695f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with IDARUBICIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-15T23:09:20.696Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:09:20.696Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "5eab9f9f24c918b7",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PALBOCICLIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8885714285714286,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8440000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8876,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PALBOCICLIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with PALBOCICLIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T23:10:20.875Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:10:20.875Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "096613a2eb7ec673",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VANDETANIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8885714285714286,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8440000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8876,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VANDETANIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with VANDETANIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T23:10:20.900Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:10:20.900Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "877308b7a8c139ea",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ENTRECTINIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8885714285714286,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8440000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8876,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ENTRECTINIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ENTRECTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T23:10:20.929Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:10:20.929Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "ce8fd5c378961621",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8885714285714286,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8440000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8501000000000001,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ADAVOSERTIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T23:10:20.955Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:10:20.955Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "33806bdc60ff1d18",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AST-487 may be repurposed to treat parkinson's disease",
      "confidence": 0.8885714285714286,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8440000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8501000000000001,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AST-487 may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with AST-487 across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-15T23:10:20.982Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:10:20.982Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "edccc218744f7f10",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "REGORAFENIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets EGFR, PDGFRA, PTEN which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PDGFRA",
          "description": "Drug targets gene associated with disease",
          "weight": 0.37
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PDGFRA",
          "description": "Drug targets gene associated with disease",
          "weight": 0.37
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "REGORAFENIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with REGORAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T23:11:10.049Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:11:10.049Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f0eed1b959b16ef6",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T23:11:10.073Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:11:10.073Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "43586a8e53e0a9cc",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T23:11:10.094Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:11:10.094Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "d6f68168621c344f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T23:11:10.115Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:11:10.115Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "e1c04e8681d4030f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-15T23:11:10.137Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:11:10.137Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "96f42e9cd97e08de",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "METFORMIN may be repurposed to treat type 2 diabetes",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets PPARG, TCF7L2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "METFORMIN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with METFORMIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T23:12:00.241Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:12:00.241Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "60680059ea42b925",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8799999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8319999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8828,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with TROGLITAZONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T23:12:00.277Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:12:00.277Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "584d7ecf22aa1c66",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8799999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8319999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8828,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with ESTRADIOL VALERATE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T23:12:00.309Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:12:00.309Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "05aa71e7066822e8",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GLYBURIDE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8799999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8319999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8828,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GLYBURIDE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with GLYBURIDE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T23:12:00.339Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:12:00.339Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "dd90e8f74ae84b22",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
      "confidence": 0.856,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7984000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.86936,
      "mechanism": "Targets PPARG which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with PROPYLPARABEN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-15T23:12:00.371Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:12:00.371Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "136bfc8d93dac91a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for triple-negative breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "triple-negative breast cancer",
      "analysisTimestamp": "2026-01-15T23:45:50.048Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:45:50.048Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "851a27e1a01882d0",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PALBOCICLIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8984615384615384,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8578461538461539,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8931384615384614,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PALBOCICLIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with PALBOCICLIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-15T23:57:47.008Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:57:47.008Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "2ef4a6dabb3ae1e2",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VANDETANIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8984615384615384,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8578461538461539,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8931384615384614,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VANDETANIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with VANDETANIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-15T23:57:47.037Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:57:47.037Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "c8b21eca31cc3063",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ENTRECTINIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8984615384615384,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8578461538461539,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8931384615384614,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ENTRECTINIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with ENTRECTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-15T23:57:47.066Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:57:47.066Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "54a31dab4dbd93e9",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ADAVOSERTIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8984615384615384,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8578461538461539,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8556384615384616,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ADAVOSERTIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with ADAVOSERTIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-15T23:57:47.093Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:57:47.093Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "a22b36395afd4f68",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AST-487 may be repurposed to treat Parkinson's disease",
      "confidence": 0.8984615384615384,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8578461538461539,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8556384615384616,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AST-487 may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with AST-487 across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-15T23:57:47.121Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-15T23:57:47.121Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "5e2ad8ecddea4c26",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.743
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.839
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-16T02:29:27.425Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:29:27.425Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "c58d9e19cf9a5c5a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-16T02:29:27.457Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:29:27.457Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "ba4a04f697694c02",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-16T02:29:27.489Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:29:27.489Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "38532925ac7e8f03",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-16T02:29:27.521Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:29:27.521Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "7533d2c88b06a6a5",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat breast cancer",
      "confidence": 0.86,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.804,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8341000000000001,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.659
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for breast cancer",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "breast cancer",
      "analysisTimestamp": "2026-01-16T02:29:27.559Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:29:27.559Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "53bf6de26c0959ce",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "SORAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "SORAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with SORAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-16T02:29:45.623Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:29:45.623Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "964b014131f4cb27",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "BINIMETINIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "BINIMETINIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with BINIMETINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-16T02:29:45.662Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:29:45.662Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "cfe0f1f316ad9698",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DABRAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DABRAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with DABRAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-16T02:29:45.698Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:29:45.698Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b01415b224524c60",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VEMURAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VEMURAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with VEMURAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-16T02:29:45.735Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:29:45.735Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "4c7c972757117bee",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with TRAMETINIB DIMETHYL SULFOXIDE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-16T02:29:45.773Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:29:45.773Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "c9282e06b6f385b0",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LECANEMAB may be repurposed to treat alzheimer's disease",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets APOE, APP which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LECANEMAB may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LECANEMAB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-16T02:31:54.041Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:31:54.041Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "a4c841a20a927eaf",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRIAMCINOLONE may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with TRIAMCINOLONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-16T02:31:54.078Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:31:54.078Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "0019cb874eebb0cb",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PRAVASTATIN SODIUM may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with PRAVASTATIN SODIUM across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-16T02:31:54.113Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:31:54.113Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "4e32209a1cc98984",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LUTEIN may be repurposed to treat alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LUTEIN may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with LUTEIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-16T02:31:54.153Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:31:54.153Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "c07ba9ce3b56b059",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
      "confidence": 0.836595744680851,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7712340425531914,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8584936170212765,
      "mechanism": "Targets APP, PSEN1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "NIROGACESTAT may be repurposed to treat alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for alzheimer's disease",
          "2. Treat with NIROGACESTAT across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "84% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "alzheimer's disease",
      "analysisTimestamp": "2026-01-16T02:31:54.192Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:31:54.192Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "41a97fa4691548da",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets DNMT3A, FLT3, NPM1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "NPM1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.656
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DAUNORUBICIN LIPOSOMAL across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-16T02:32:40.019Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:32:40.019Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "7db55d37e90f6b32",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with AZACITIDINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-16T02:32:40.054Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:32:40.054Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "c684c6b97fbac49c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with QUIZARTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-16T02:32:40.089Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:32:40.089Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "3ae79bb5d1a32820",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DECITABINE may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DECITABINE may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with DECITABINE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-16T02:32:40.125Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:32:40.125Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "404b3ac3690f5477",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
      "confidence": 0.8671428571428571,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.814,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8756,
      "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "DNMT3A",
          "description": "Drug targets gene associated with disease",
          "weight": 0.817
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        },
        {
          "type": "target_overlap",
          "gene": "FLT3",
          "description": "Drug targets gene associated with disease",
          "weight": 0.809
        }
      ],
      "experimentalDesign": {
        "hypothesis": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
          "2. Treat with IDARUBICIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "87% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "DNMT3A",
        "FLT3",
        "NPM1"
      ],
      "disease": "acute myeloid leukemia",
      "analysisTimestamp": "2026-01-16T02:32:40.161Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:32:40.161Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "a5d4a3df2260d2ad",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PALBOCICLIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PALBOCICLIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with PALBOCICLIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-16T02:33:37.011Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:33:37.011Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f26f7b874cd9be60",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VANDETANIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VANDETANIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with VANDETANIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-16T02:33:37.047Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:33:37.047Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "258bca626466163a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ENTRECTINIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ENTRECTINIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ENTRECTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-16T02:33:37.081Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:33:37.081Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "4144fa1f602e8273",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8527666666666667,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ADAVOSERTIB may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with ADAVOSERTIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-16T02:33:37.108Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:33:37.108Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "32c8d14a19fbb946",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AST-487 may be repurposed to treat parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8527666666666667,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AST-487 may be repurposed to treat parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for parkinson's disease",
          "2. Treat with AST-487 across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PRKN",
        "SNCA"
      ],
      "disease": "parkinson's disease",
      "analysisTimestamp": "2026-01-16T02:33:37.140Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:33:37.140Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "8e9b9bc0faf21841",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "REGORAFENIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets EGFR, PDGFRA, PTEN which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PDGFRA",
          "description": "Drug targets gene associated with disease",
          "weight": 0.37
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "PTEN",
          "description": "Drug targets gene associated with disease",
          "weight": 0.602
        },
        {
          "type": "target_overlap",
          "gene": "PDGFRA",
          "description": "Drug targets gene associated with disease",
          "weight": 0.37
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "REGORAFENIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with REGORAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-16T02:34:17.690Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:34:17.690Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "54daa199ee2e319f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DACOMITINIB ANHYDROUS may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with DACOMITINIB ANHYDROUS across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-16T02:34:17.720Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:34:17.720Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "94ffc368469877b7",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "OSIMERTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "OSIMERTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with OSIMERTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-16T02:34:17.751Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:34:17.751Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "c918fd5cc929c65c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GEFITINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GEFITINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with GEFITINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-16T02:34:17.790Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:34:17.790Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "7bc4a91a5837a4dd",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ERLOTINIB may be repurposed to treat glioblastoma",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8565,
      "mechanism": "Targets EGFR which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.654
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ERLOTINIB may be repurposed to treat glioblastoma",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for glioblastoma",
          "2. Treat with ERLOTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "EGFR",
        "PDGFRA",
        "PTEN"
      ],
      "disease": "glioblastoma",
      "analysisTimestamp": "2026-01-16T02:34:17.832Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:34:17.832Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "76c6190d4998afd4",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "METFORMIN may be repurposed to treat type 2 diabetes",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets PPARG, TCF7L2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "TCF7L2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.676
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "METFORMIN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with METFORMIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-16T02:35:04.940Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:35:04.940Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "a2d429ca76eae90f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8799999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8319999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8828,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TROGLITAZONE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with TROGLITAZONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-16T02:35:04.972Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:35:04.972Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "73da51e6ac431dbd",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8799999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8319999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8828,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ESTRADIOL VALERATE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with ESTRADIOL VALERATE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-16T02:35:05.008Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:35:05.008Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "0ca75940f37dcc92",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "GLYBURIDE may be repurposed to treat type 2 diabetes",
      "confidence": 0.8799999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8319999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8828,
      "mechanism": "Targets PPARG, SLC2A4 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "SLC2A4",
          "description": "Drug targets gene associated with disease",
          "weight": 0.251
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "GLYBURIDE may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with GLYBURIDE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-16T02:35:05.037Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:35:05.037Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "727c1ddb59b8d35c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
      "confidence": 0.856,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7984000000000001,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.86936,
      "mechanism": "Targets PPARG which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        },
        {
          "type": "target_overlap",
          "gene": "PPARG",
          "description": "Drug targets gene associated with disease",
          "weight": 0.846
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PROPYLPARABEN may be repurposed to treat type 2 diabetes",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for type 2 diabetes",
          "2. Treat with PROPYLPARABEN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "86% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "PPARG",
        "SLC2A4",
        "TCF7L2"
      ],
      "disease": "type 2 diabetes",
      "analysisTimestamp": "2026-01-16T02:35:05.074Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:35:05.074Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "db1eb968a65e1f8a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PALBOCICLIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8984615384615384,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8578461538461539,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8931384615384614,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PALBOCICLIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with PALBOCICLIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-16T02:46:51.811Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:46:51.811Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "2a87b70f1bed3de2",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VANDETANIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8984615384615384,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8578461538461539,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8931384615384614,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VANDETANIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with VANDETANIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-16T02:46:51.839Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:46:51.839Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f3ff732e5cd39523",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ENTRECTINIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8984615384615384,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8578461538461539,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8931384615384614,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ENTRECTINIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with ENTRECTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-16T02:46:51.867Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:46:51.867Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "75aa64607a65fb5f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ADAVOSERTIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8984615384615384,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8578461538461539,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8556384615384616,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ADAVOSERTIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with ADAVOSERTIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-16T02:46:51.899Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:46:51.899Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "2ce50475b933c2b9",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AST-487 may be repurposed to treat Parkinson's disease",
      "confidence": 0.8984615384615384,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8578461538461539,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8556384615384616,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AST-487 may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with AST-487 across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-16T02:46:51.932Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T02:46:51.932Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "4e34869fd3fc7c7e",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LECANEMAB may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets APOE, APP which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LECANEMAB may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with LECANEMAB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-16T03:10:23.936Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:10:23.936Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "77424dc8a6a0c894",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRIAMCINOLONE may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRIAMCINOLONE may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with TRIAMCINOLONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-16T03:10:23.974Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:10:23.974Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "6dc4febf1f63b478",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PRAVASTATIN SODIUM may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PRAVASTATIN SODIUM may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with PRAVASTATIN SODIUM across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-16T03:10:24.010Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:10:24.010Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "e02713d978c4d165",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LUTEIN may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LUTEIN may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with LUTEIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-16T03:10:24.048Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:10:24.048Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "bd564c9a0f38473e",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "NIROGACESTAT may be repurposed to treat Alzheimer's disease",
      "confidence": 0.836595744680851,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7712340425531914,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8584936170212765,
      "mechanism": "Targets APP, PSEN1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "NIROGACESTAT may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with NIROGACESTAT across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "84% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-16T03:10:24.087Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:10:24.087Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "06aef2f77f479e5a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for triple-negative breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "triple-negative breast cancer",
      "analysisTimestamp": "2026-01-16T03:22:10.603Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:22:10.603Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "69d07d0e652635a1",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "SORAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "SORAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with SORAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-16T03:33:44.332Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:33:44.332Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "1f0c5d4a612ea587",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "BINIMETINIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "BINIMETINIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with BINIMETINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-16T03:33:44.357Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:33:44.357Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "2ea30daa27c47201",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DABRAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DABRAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with DABRAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-16T03:33:44.378Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:33:44.378Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "72e87ff6c1cc561a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VEMURAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VEMURAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with VEMURAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-16T03:33:44.400Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:33:44.400Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "e70b4e65bdb9f9f2",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with TRAMETINIB DIMETHYL SULFOXIDE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-16T03:33:44.422Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:33:44.422Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "9612fd5e2d05c77f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PALBOCICLIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PALBOCICLIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with PALBOCICLIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-16T03:36:48.130Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:36:48.130Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "7f210826d4fe8409",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VANDETANIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VANDETANIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with VANDETANIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-16T03:36:48.162Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:36:48.162Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "3a14248f42b96ff3",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ENTRECTINIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8902666666666665,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ENTRECTINIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with ENTRECTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-16T03:36:48.190Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:36:48.190Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "ea93c4a52260ae6b",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ADAVOSERTIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8527666666666667,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ADAVOSERTIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with ADAVOSERTIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-16T03:36:48.224Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:36:48.224Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "659267635e7fcbd4",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AST-487 may be repurposed to treat Parkinson's disease",
      "confidence": 0.8933333333333333,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8506666666666667,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8527666666666667,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AST-487 may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with AST-487 across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "89% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-16T03:36:48.260Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:36:48.260Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "e4817fa77c5fb2cc",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LECANEMAB may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets APOE, APP which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LECANEMAB may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with LECANEMAB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-16T03:38:08.645Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:38:08.645Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "a3cad669aca3685f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRIAMCINOLONE may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRIAMCINOLONE may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with TRIAMCINOLONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-16T03:38:08.687Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:38:08.687Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "142abd6da73431c8",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PRAVASTATIN SODIUM may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PRAVASTATIN SODIUM may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with PRAVASTATIN SODIUM across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-16T03:38:08.724Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:38:08.724Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "9cf680233872db46",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LUTEIN may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LUTEIN may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with LUTEIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-16T03:38:08.770Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:38:08.770Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "c8ecc6c893d9f52b",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "NIROGACESTAT may be repurposed to treat Alzheimer's disease",
      "confidence": 0.836595744680851,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7712340425531914,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8584936170212765,
      "mechanism": "Targets APP, PSEN1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "NIROGACESTAT may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with NIROGACESTAT across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "84% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-16T03:38:08.814Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:38:08.814Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "65080a3b6b45e785",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for triple-negative breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "triple-negative breast cancer",
      "analysisTimestamp": "2026-01-16T03:46:17.740Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T03:46:17.740Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "6a151ea4bbf3a70b",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for triple-negative breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "triple-negative breast cancer",
      "analysisTimestamp": "2026-01-16T13:32:17.059Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T13:32:17.059Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "a163bc9d58579f84",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PALBOCICLIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8984615384615384,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8578461538461539,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8931384615384614,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PALBOCICLIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with PALBOCICLIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-16T13:35:52.498Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T13:35:52.498Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "fb64a298cfc9fe7f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VANDETANIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8984615384615384,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8578461538461539,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8931384615384614,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VANDETANIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with VANDETANIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-16T13:35:52.536Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T13:35:52.536Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "95ff7e4ee462b6f8",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ENTRECTINIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8984615384615384,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8578461538461539,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8931384615384614,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ENTRECTINIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with ENTRECTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-16T13:35:52.573Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T13:35:52.573Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "9bd6b34e06de890a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ADAVOSERTIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8984615384615384,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8578461538461539,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8556384615384616,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ADAVOSERTIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with ADAVOSERTIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-16T13:35:52.609Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T13:35:52.609Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "e7ea6b6bc7e4fbe2",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AST-487 may be repurposed to treat Parkinson's disease",
      "confidence": 0.8984615384615384,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8578461538461539,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8556384615384616,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AST-487 may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with AST-487 across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-16T13:35:52.644Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T13:35:52.644Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f1e2a65eac1236ce",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "SORAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "SORAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with SORAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-16T14:16:10.502Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T14:16:10.502Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "5b9f60cb0f0e71dd",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "BINIMETINIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "BINIMETINIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with BINIMETINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-16T14:16:10.537Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T14:16:10.537Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "d0b43f492262e2e1",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DABRAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DABRAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with DABRAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-16T14:16:10.571Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T14:16:10.571Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "f4d468c19f863579",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VEMURAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VEMURAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with VEMURAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-16T14:16:10.607Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T14:16:10.607Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "33329905dca09c67",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with TRAMETINIB DIMETHYL SULFOXIDE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-16T14:16:10.644Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T14:16:10.644Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "0397124c6387e9bb",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for triple-negative breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "triple-negative breast cancer",
      "analysisTimestamp": "2026-01-16T14:45:12.018Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T14:45:12.018Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "6e509945863b6f34",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRCA1, EGFR, TP53 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "TP53",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "BRCA1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.483
        },
        {
          "type": "target_overlap",
          "gene": "EGFR",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "CARBOPLATIN may be repurposed to treat triple-negative breast cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for triple-negative breast cancer",
          "2. Treat with CARBOPLATIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRCA1",
        "EGFR",
        "TP53"
      ],
      "disease": "triple-negative breast cancer",
      "analysisTimestamp": "2026-01-16T17:39:34.645Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T17:39:34.645Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "74ac85fa2d44bc61",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "SORAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "SORAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with SORAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-16T21:39:47.591Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T21:39:47.591Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "074eb108adf0d28e",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "BINIMETINIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "BINIMETINIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with BINIMETINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-16T21:39:47.625Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T21:39:47.625Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "1b78cd1e1143286d",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "DABRAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "DABRAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with DABRAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-16T21:39:47.652Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T21:39:47.652Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "5b500aa3690363b4",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VEMURAFENIB may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VEMURAFENIB may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with VEMURAFENIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-16T21:39:47.683Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T21:39:47.683Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "57bbf9d0b8d2c499",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets BRAF, KRAS, NRAS which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        },
        {
          "type": "target_overlap",
          "gene": "NRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.616
        },
        {
          "type": "target_overlap",
          "gene": "BRAF",
          "description": "Drug targets gene associated with disease",
          "weight": 0.692
        },
        {
          "type": "target_overlap",
          "gene": "KRAS",
          "description": "Drug targets gene associated with disease",
          "weight": 0.508
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRAMETINIB DIMETHYL SULFOXIDE may be repurposed to treat colorectal cancer",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for colorectal cancer",
          "2. Treat with TRAMETINIB DIMETHYL SULFOXIDE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "BRAF",
        "KRAS",
        "NRAS"
      ],
      "disease": "colorectal cancer",
      "analysisTimestamp": "2026-01-16T21:39:47.712Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T21:39:47.712Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "4fedb92f7334784e",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PALBOCICLIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8959999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8544,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8917599999999999,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PALBOCICLIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with PALBOCICLIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-16T21:41:10.088Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T21:41:10.088Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "ea8b505b4cf6b8c4",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "VANDETANIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8959999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8544,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8917599999999999,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "VANDETANIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with VANDETANIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-16T21:41:10.116Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T21:41:10.116Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "061ea0ad231b1d3a",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ENTRECTINIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8959999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8544,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8917599999999999,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ENTRECTINIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with ENTRECTINIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-16T21:41:10.144Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T21:41:10.144Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "dad2af47403f6bf8",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "ADAVOSERTIB may be repurposed to treat Parkinson's disease",
      "confidence": 0.8959999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8544,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.85426,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "ADAVOSERTIB may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with ADAVOSERTIB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-16T21:41:10.176Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T21:41:10.176Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "6d65deac40289d08",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "AST-487 may be repurposed to treat Parkinson's disease",
      "confidence": 0.8959999999999999,
      "novelty": 0.85,
      "impact": 0.8,
      "plausibility": 0.8544,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.85426,
      "mechanism": "Targets LRRK2 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "LRRK2",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "AST-487 may be repurposed to treat Parkinson's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Parkinson's disease",
          "2. Treat with AST-487 across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "LRRK2",
        "PARK7",
        "SNCA"
      ],
      "disease": "Parkinson's disease",
      "analysisTimestamp": "2026-01-16T21:41:10.205Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T21:41:10.205Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "64daa121bb010b52",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LECANEMAB may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8999999999999999,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8599999999999999,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8939999999999999,
      "mechanism": "Targets APOE, APP which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LECANEMAB may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with LECANEMAB across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "90% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-16T21:46:13.707Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T21:46:13.707Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "878f4b8bd0e05a55",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "TRIAMCINOLONE may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "TRIAMCINOLONE may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with TRIAMCINOLONE across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-16T21:46:13.750Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T21:46:13.750Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "b5116e1f1d75d85c",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "PRAVASTATIN SODIUM may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "PRAVASTATIN SODIUM may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with PRAVASTATIN SODIUM across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-16T21:46:13.784Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T21:46:13.784Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "86a5b026184b9f7f",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "LUTEIN may be repurposed to treat Alzheimer's disease",
      "confidence": 0.8834042553191489,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.8367659574468086,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8847063829787233,
      "mechanism": "Targets APOE which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        },
        {
          "type": "target_overlap",
          "gene": "APOE",
          "description": "Drug targets gene associated with disease",
          "weight": 0.6
        }
      ],
      "experimentalDesign": {
        "hypothesis": "LUTEIN may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with LUTEIN across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "88% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-16T21:46:13.819Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T21:46:13.819Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  },
  {
    "id": "96740084c46876b2",
    "hypothesis": {
      "type": "drug_repurposing",
      "statement": "NIROGACESTAT may be repurposed to treat Alzheimer's disease",
      "confidence": 0.836595744680851,
      "novelty": 0.85,
      "impact": 0.95,
      "plausibility": 0.7712340425531914,
      "contradictionPenalty": 0,
      "supportingEvidence": 0,
      "contradictingEvidence": 0,
      "totalScore": 0.8584936170212765,
      "mechanism": "Targets APP, PSEN1 which are implicated in disease",
      "evidence": [
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "PSEN1",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        },
        {
          "type": "target_overlap",
          "gene": "APP",
          "description": "Drug targets gene associated with disease",
          "weight": 0.3
        }
      ],
      "experimentalDesign": {
        "hypothesis": "NIROGACESTAT may be repurposed to treat Alzheimer's disease",
        "experimentType": "In Vitro Efficacy + Mechanism Validation",
        "protocol": [
          "1. Select disease-relevant cell lines or organoids for Alzheimer's disease",
          "2. Treat with NIROGACESTAT across a dose range (8-12 concentrations)",
          "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
          "4. Validate on-target engagement with western blot or target-specific assays"
        ],
        "controls": [
          "Vehicle control (DMSO)",
          "Known standard-of-care drug (positive control)",
          "Off-target negative control compound"
        ],
        "readouts": [
          "Dose-response curve and IC50",
          "Biomarker modulation (pathway activation/inhibition)",
          "Cell cycle profiling (flow cytometry)",
          "Transcriptomic response signature"
        ],
        "timeline": "3-6 weeks",
        "estimatedCost": "$10,000-20,000",
        "successCriteria": "Significant efficacy vs control with IC50 < 1 M and biomarker modulation",
        "predictedOutcome": "84% probability of efficacy",
        "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
      }
    },
    "context": {
      "genes": [
        "APOE",
        "APP",
        "PSEN1"
      ],
      "disease": "Alzheimer's disease",
      "analysisTimestamp": "2026-01-16T21:46:13.851Z"
    },
    "validation": {
      "outcome": "not_tested",
      "experimentalResults": null,
      "validatedBy": null,
      "validationDate": null,
      "pmid": null,
      "notes": ""
    },
    "metadata": {
      "createdAt": "2026-01-16T21:46:13.852Z",
      "viewCount": 0,
      "shareCount": 0,
      "downloadCount": 0
    }
  }
]